В. В. Бредер
Impact in
- Hepatology top 0.2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 57
- Cancer Immunotherapy and Biomarkers 28
- Colorectal Cancer Treatments and Studies 21
- Lung Cancer Research Studies 9
- Hepatology 52
- Hepatocellular Carcinoma Treatment and Prognosis 49
- Co-authors
- Masatoshi Kudo (29 shared papers)Philippe Merle (25 shared papers)Ann‐Lii Cheng (20 shared papers)Andrew X. Zhu (16 shared papers)Richard S. Finn (16 shared papers)Ho Yeong Lim (15 shared papers)Stephen L. Chan (13 shared papers)Peter R. Galle (13 shared papers)
- Journals
- Journal of Clinical Oncology (21 papers)Annals of Oncology (15 papers)Journal of Thoracic Oncology (3 papers)Liver Cancer (2 papers)Journal of Hepatology (2 papers)
- Partner nations
- RussiaUnited StatesFrance
In The Last Decade
В. В. Бредер
81 papers receiving 3.9k citations
В. В. Бредер's Hit Papers
Peers
Comparison fields: 5 of 71
- Hepatology 2.2k
- Oncology 1.4k
- Pathology and Forensic Medicine 551
- Cancer Research 370
- Immunology 510
Countries citing papers authored by В. В. Бредер
This map shows the geographic impact of В. В. Бредер's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by В. В. Бредер with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites В. В. Бредер more than expected).
Fields of papers citing papers by В. В. Бредер
This network shows the impact of papers produced by В. В. Бредер. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by В. В. Бредер. The network helps show where В. В. Бредер may publish in the future.
Co-authors
The 25 scholars most cited alongside В. В. Бредер, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 108 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial Hit paper breakdown → | 2019 | 1329 |
| 2 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Hit paper breakdown → | 2021 | 964 |
| 3 | Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Hit paper breakdown → | 2022 | 267 |
| 4 | IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). Hit paper breakdown → | 2021 | 233 |
| 5 | Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer Hit paper breakdown → | 2021 | 169 |
| 6 | 2019 | 159 | |
| 7 | 2019 | 152 | |
| 8 | Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2024 | 58 |
| 9 | 2021 | 48 | |
| 10 | 2019 | 44 | |
| 11 | 2021 | 40 | |
| 12 | 2018 | 37 | |
| 13 | 2020 | 34 | |
| 14 | 2023 | 32 | |
| 15 | 2016 | 27 | |
| 16 | 2020 | 27 | |
| 17 | 2020 | 22 | |
| 18 | 2017 | 22 | |
| 19 | 2022 | 19 | |
| 20 | 2021 | 16 |
About В. В. Бредер
В. В. Бредер is a scholar working on Oncology, Hepatology, Pulmonary and Respiratory Medicine, Epidemiology and Cancer Research, having authored 108 papers that have together received 3.9k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (49 papers), Cancer Immunotherapy and Biomarkers (28 papers), Lung Cancer Treatments and Mutations (26 papers), Colorectal Cancer Treatments and Studies (21 papers), Liver Disease Diagnosis and Treatment (19 papers), Lung Cancer Research Studies (9 papers), Cancer Genomics and Diagnostics (8 papers) and Lung Cancer Diagnosis and Treatment (8 papers). The work is most often cited by research in Hepatology (2.2k citations), Oncology (1.4k citations), Pathology and Forensic Medicine (551 citations), Cancer Research (370 citations) and Immunology (510 citations). В. В. Бредер has collaborated with scholars based in Russia, United States and France. Frequent co-authors include Masatoshi Kudo, Philippe Merle, Ann‐Lii Cheng, Andrew X. Zhu, Richard S. Finn, Ho Yeong Lim, Stephen L. Chan, Peter R. Galle, Ahmed O. Kaseb and Bruno Daniele. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Liver Cancer and Journal of Hepatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.